Cancer Drugs Move To NICE's Fast-Track Appraisal Process
This article was originally published in The Pink Sheet Daily
Executive Summary
Guidances for some products could be issued by the end of the year under a new rapid review system.
You may also be interested in...
NICE Draft Negs Tarceva, Alimta For Treatment Of NSCLC
Neither Roche's erlotinib or Lilly's pemetrexed represent "good use of scarce" resources, NICE says in preliminary reports.
NICE Draft Negs Tarceva, Alimta For Treatment Of NSCLC
Neither Roche's erlotinib or Lilly's pemetrexed represent "good use of scarce" resources, NICE says in preliminary reports.
NICE Adds Arthritis Drugs To Fast Track Appraisal Pathway
Clinical and cost effectiveness of Rituxan, Orencia, Humira, and Arava to be evaluated under single technology appraisal process.